Automated Managed Material Dispenser to accommodate Fresenius Kabi Simplist® MicroVault® Pre-loaded Syringes
MOUNTAIN See, Calif. & LAKE ZURICH, Unwell., November 10, 2021–(Company WIRE)–Omnicell, Inc. (Nasdaq:OMCL), a leading provider of treatment administration answers and adherence resources for health devices and pharmacies, and Fresenius Kabi, a world wide well being care enterprise that specializes in medications and systems for infusion, transfusion, and scientific nutrition, are collaborating to offer U.S. hospitals and health methods with revolutionary new pharmacy technology made to aid protection and efficiency in dispensing of controlled substances in affected individual treatment locations.
Taking care of managed substances is a major challenge for hospitals and clinics. According to a modern analyze, additional than 148 million doses of drugs were being misplaced in 2019, compromising both individual and workforce safety.1
Omnicell’s Managed Compound Dispenser (CSD) is a main higher-volume, automated one dose dispensing option designed to support pharmacies much better regulate controlled substances, decrease diversion, and save nursing time. By delivering only one particular dose at a time, the CSD is made to remove the will need for countbacks and lessen the time expected to take care of discrepancies to supply nurses far more time for immediate affected person care and discourage diversion.2
Through its romance with Fresenius Kabi, Omnicell has intended new cassettes for its CSD particularly for Fresenius Kabi Simplist® MicroVault® prefilled syringes that will present customers additional flexibility with their treatment source chain and enhanced managed material administration initiatives. The new Fresenius Kabi cassettes for the Omnicell CSD are obtainable now.
Fresenius Kabi Simplist® MicroVault® prefilled syringes are employed by hospitals in the United States in an work to help reduce the volume of time nurses devote preparing doses and documenting waste. The error charge is four times reduced employing these prefilled syringes compared with standard treatment administration methods.3 The new cassettes for the Omnicell CSD will accommodate MicroVault® packaging for a range of very low-dose narcotic remedies such as morphine, hydromorphone, and fentanyl. The syringes are maker-prepared in the United States, with a 24-month shelf life, and are single-device doses, supporting most effective practices for medication administration.
“Omnicell is dedicated to addressing the most important issues in pharmacy care shipping as a result of know-how,” mentioned Nish Parekh, Omnicell’s Vice President of Product or service Management for Issue of Treatment Options. “Via innovative collaborations with health care leaders like Fresenius Kabi, we’re delivering the alternatives created to assistance our prospects regulate controlled substances, decrease diversion, optimize inventory, and enhance medical workflows to support optimum care and affected person protection.”
“Fresenius Kabi is committed to treatment security and the accountable use of managed substances,” reported Angie Lindsey, Vice President of Marketing and advertising for Fresenius Kabi Usa. “The blend of Omnicell’s Controlled Substance Dispenser automation workflow with Fresenius Kabi Simplist® MicroVault® prefilled syringes will supply healthcare companies sophisticated resources and engineering to obtain these aims.”
The Fresenius Kabi-Omnicell relationship and providing is an significant step towards the eyesight of the Autonomous Pharmacy, a roadmap to produce a zero-error, totally automated medicine management infrastructure. By way of Omnicell’s sector major medication management portfolio of hardware, software package, and technological innovation-enabled products and services sent through the cloud, many well being methods and retail pharmacies are knowing how connected know-how and intelligence can assistance resolve some of the most urgent problems in medication management.
About Fresenius Kabi
Fresenius Kabi (www.fresenius-kabi.com/us) is a international overall health care firm that specializes in medications and technologies for infusion, transfusion and scientific diet. The company’s solutions and products and services are used to enable deal with essential and chronic conditions. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Undesirable Homburg, Germany. To learn about U.S. career options at Fresenius Kabi, go to us at www.fresenius-kabi.com/us/join-us. Discover a lot more about the Simplist® ready-to-administer prefilled syringe portfolio at www.simplist-us.com.
Considering the fact that 1992, Omnicell has been fully commited to reworking the pharmacy care supply design to significantly increase results and lessen fees. As a result of the vision of the autonomous pharmacy, a blend of automation, intelligence, and technologies-enabled expert services, run by a cloud data system, Omnicell supports additional economical means to regulate medications across all treatment options. Around 7,000 facilities throughout the world use Omnicell automation and analytics alternatives to enable raise operational performance, minimize medicine glitches, deliver actionable intelligence, and boost affected individual protection. A lot more than 60,000 institutional and retail pharmacies throughout North The united states and the United Kingdom leverage Omnicell’s progressive medication adherence and populace well being options to boost affected person engagement and adherence to prescriptions, encouraging to lessen expensive medical center readmissions. To master far more, take a look at www.omnicell.com.
Selected statements contained in this push release relate to long run options and goals concerning Omnicell’s items and services. These statements are “forward-looking statements” inside the indicating of the Non-public Securities Litigation Reform Act of 1995. Real outcomes and other occasions could differ noticeably from those people contemplated by ahead-looking statements thanks to various aspects that entail significant acknowledged and unknown threats and uncertainties. These risks and uncertainties include things like, among other issues, those described in the Danger Variables part of Omnicell’s most new yearly report on Type 10-K and quarterly report on Kind 10-Q and in the Company’s other filings with the U.S. Securities and Trade Commission. Ahead-seeking statements should be regarded in gentle of these dangers and uncertainties. Investors are cautioned not to area undue reliance on forward-wanting statements. All forward searching statements contained in this push launch talk only as of the day of this push release. Omnicell undertakes no obligation to update this sort of statements, regardless of whether as a final result of modified conditions, new data, upcoming events, or normally, besides as necessary by regulation.
OMNICELL is a registered trademark and the Omnicell symbol is a trademark of Omnicell, Inc. SIMPLIST AND MICROVAULT are registered trademarks of Fresenius Kabi Usa, LLC. All rights reserved.
2Based on Omnicell shopper facts examination
3Hertig JB, Degnan DD, Scott CR, Lenz JR, Li X, Anderson CM. A comparison of mistake premiums amongst intravenous drive strategies: a possible, multisite, observational study. J Affected person Saf. 201814(1):60-65.
Check out supply variation on businesswire.com: https://www.businesswire.com/information/dwelling/20211110005628/en/